Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer  Myriad Genetics (NASDAQ: MYGN) announced FDA approval of the MyChoice CDx Test as the companion diagnostic for Zejula (niraparib) in advanced ovarian cancer in the United States. The approval is based on final PRIMA trial data and establishes MyChoice CDx as the only FDA-authorized CDx for Zejula.The test uses next-generation sequencing to assess BRCA1/2 (including large rearrangements) and a tumor genomic instability score (LOH, TAI, LST) to determine HRD status for treatment decisions.

#MYGN Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer 

www.stocktitan.net/news/MYGN/myriad-genetic...

#MYGN Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs

www.stocktitan.net/news/MYGN/myriad-genetic...

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution Highl ights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds 1 of $8.1 million , consistent with management expectations . Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11%

#MYGN Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

www.stocktitan.net/news/MYGN/myriad-genetic...

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine,

#MYGN Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

www.stocktitan.net/news/MYGN/myriad-genetic...

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology Myriad Genetics (NASDAQ: MYGN) announced the publication of clinical data for its Precise MRD test in The Lancet Oncology. The study focused on patients with oligometastatic clear-cell renal cell carcinoma (ccRCC) and demonstrated significant results in detecting circulating tumor DNA (ctDNA).The Phase 2 trial revealed that 94% of patients had ctDNA levels below 100 ppm at baseline. Patients testing negative with Precise MRD maintained metastasis-directed therapy for a median of 54 months, compared to 27 months for ctDNA-positive patients. Notably, ctDNA-negative patients showed strong survival rates of 94% at two years and 87% at three years.

#MYGN Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

www.stocktitan.net/news/MYGN/myriad-genetic...

BREAKING NEWS: ( NASDAQ: #MYGN ) PRISM Mid-Day Movers: Telehealth Turbulence and Global Health Dilution

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum Myriad Genetics (NASDAQ:MYGN) reported Q2 2025 revenue of $213.1 million, up 1% year-over-year, and raised its 2025 revenue guidance to $818-828 million. The company's hereditary cancer testing showed strong performance with 9% revenue growth and 10% volume growth in Oncology.Q2 2025 highlights include improved gross margin of 71.2% (up 160 basis points YoY) and a GAAP net loss of $330.5 million ($3.57 per share), primarily due to non-cash impairment charges of $316.7 million. The company secured a new $200 million credit facility to enhance financial flexibility.Myriad announced a strategic shift focusing on three pillars: accelerating growth in Cancer Care Continuum, maintaining growth in Prenatal and Mental Health, and driving sustained profitable growth. The company plans to launch its proprietary MRD test in H1 2026 and expects high single to low double-digit revenue growth over the next five years.

#MYGN Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum

www.stocktitan.net/news/MYGN/myriad-genetic...

Myriad Genetics Just Secured $200M Strategic Financing: Here's What It Means for Growth Major financing deal provides Myriad with $125M immediate capital plus $75M in options. Learn how this strategic partnership with OrbiMed fuels expansion plans. See details.

#MYGN Myriad Genetics Announces New $200 Million Credit Facility

www.stocktitan.net/news/MYGN/myriad-genetic...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#RZLV, #MYGN, #PTON, #STM, #RRR

#OptionFlow #OptionsTrading #Trading

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#META, #APLD, #MRK, #PTON, #MYGN

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #JD 3.4x
2. #RZLV 3.0x
3. #MYGN 2.7x
4. #PTON 2.5x
5. #STM 2.2x

#OptionFlow #OptionsTrading #Trading

Breakthrough Prenatal Screen Combines 4 Tests in 1 Blood Draw - No Father Sample Needed New FirstGene screen delivers 98.6% accurate prenatal testing from single blood draw, eliminating need for paternal testing. 5,000-patient study now enrolling. Learn more.

#MYGN Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

www.stocktitan.net/news/MYGN/myriad-genetic...

Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types Myriad Genetics (MYGN) revealed promising clinical data from the MONSTAR-SCREEN-3 study for their Precise MRD Test, demonstrating 100% detection of circulating tumor DNA (ctDNA) at baseline across multiple cancer types. The study, conducted with Japan's National Cancer Center Hospital East, showed the test can detect tumor fractions as low as 0.0001% and successfully created personalized whole-genome sequencing panels for 97.3% of patients. Notably, 60% of ctDNA-positive patients one month post-surgery had ultra-low tumor fractions only detectable by Precise MRD's enhanced sensitivity. These patients showed significantly worse disease-free survival compared to ctDNA-negative patients. The test also demonstrated ability to predict pathological complete response during neoadjuvant chemotherapy and showed earlier recurrence detection compared to imaging.

#MYGN Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types

www.stocktitan.net/news/MYGN/myriad-genetic...

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting Myriad Genetics (NASDAQ: MYGN) will present seven new research studies at the 2025 ASCO Annual Meeting, showcasing advancements in oncology and precision medicine. Key highlights include the MONSTAR-SCREEN-3 study, demonstrating successful pan-cancer implementation of whole genome sequencing-based personalized ctDNA detection, achieving 100% baseline detection across tumor types. The company announced upcoming product innovations including: Precise MRD Test (commercial launch in 2026), Prolaris Prostate Cancer Test with PATHOMIQ AI technology (early 2026), expanded MyRisk Hereditary Cancer Test panel (late 2025), and full EMR integration with Flatiron's OncoEMR and Epic platforms (late 2025). These developments reflect Myriad's commitment to advancing personalized cancer care through genetic and tumor genomic testing solutions.

#MYGN Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

www.stocktitan.net/news/MYGN/myriad-genetic...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Wed May 7th - #WRD #SYTA #OKYO #KAVL #SNCR #MYGN #LFVN #HAIN #GDRX #YAAS #ARIS #BGS #EPC #GFR #MAGN #RVLV #VSTS #ALZN #BNR #CEVA - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology Myriad Genetics (NASDAQ: MYGN) announced the publication of a real-world study in JCO Precision Oncology demonstrating the effectiveness of their RiskScore® breast cancer risk assessment tool. The study showed that RiskScore predicted different risk levels than the Tyrer-Cuzick model for nearly 20% of patients. Notably, patients with ≥20% lifetime breast cancer risk identified by RiskScore were more likely to receive guidelines-aligned screening, including mammography, breast MRI, and genetic counseling.RiskScore, which is integrated into Myriad's MyRisk® Hereditary Cancer Test, combines a polygenic risk score (PRS) validated for all ancestries with the Tyrer-Cuzick model to predict five-year and remaining lifetime breast cancer risk. The study findings suggest that clinicians are effectively utilizing RiskScore results to make informed decisions about patient risk management and screening recommendations.

#MYGN Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

www.stocktitan.net/news/MYGN/myriad-genetic...

Myriad Genetics Earnings: Revenue Drops as UnitedHealth Cuts Coverage, Company Reduces Full-Year Outlook Mixed Q1 results show 11% prenatal growth but 20% pharmacogenomics decline. See how UnitedHealth coverage changes impact outlook and new cost-cutting measures. Get details.

#MYGN Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

www.stocktitan.net/news/MYGN/myriad-genetic...

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CEP, #SEDG, #SOFI, #MYGN, #MPWR

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CEP, #MYGN, #SMCI, #RIOT, #WOLF

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #CEP 54% OTM
2. #PLTR 28% OTM
3. #MYGN 24% OTM
4. #SMCI 23% OTM
5. #RIOT 21% OTM

#OptionFlow #OptionsTrading #Trading

New Study: Depression Patients See 40% Drop in Drug Complications with GeneSight Genetic Test Clinical study reveals GeneSight's genetic testing dramatically reduces psychiatric hospitalizations and improves medication matching. See full efficacy data.

#MYGN Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

www.stocktitan.net/news/MYGN/myriad-genetic...

Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio Myriad Genetics (NASDAQ: MYGN) has entered into a strategic collaboration with PATHOMIQ to exclusively license PATHOMIQ_PRAD, an AI technology platform for prostate cancer, in the United States. The partnership enhances Myriad's Oncology Solutions by combining molecular and AI-powered testing capabilities to inform treatment decisions for prostate cancer patients.PATHOMIQ_PRAD's AI model delivers results within 1-2 days of receiving digital images and has demonstrated high prediction accuracy in both Caucasian and African American patient cohorts. The platform complements Myriad's existing Prolaris® Prostate Cancer Prognostic Test and can predict disease recurrence after initial therapy.The collaboration aims to accelerate achieving Simon level 1 evidence for both tests. While currently specific for post-surgical prostate cancer patients, the foundational model has potential applications across all solid tumor cancers diagnosed through H&E staining biopsies. Myriad plans to launch its first AI-driven prostate cancer clinical test later in 2025.

#MYGN Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

www.stocktitan.net/news/MYGN/myriad-genetic...

Myriad Genetics Sets Stage for Major Q4 Financial Reveal: 3 Key Investor Conferences Follow Myriad Genetics announces Q4 and full-year 2024 earnings release, followed by strategic presentations at three major healthcare investor conferences in March.

#MYGN Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

www.stocktitan.net/news/MYGN/myriad-genetic...

Major Healthcare Partnership: Myriad's Advanced Cancer Risk Test Now Available to Million-Plus Patients Myriad Genetics partners with INTERLINK's CancerCARE, bringing MyRisk hereditary cancer testing to over 1M members. Test screens 48 genes across 11 cancers with personalized risk assessment.

#MYGN Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test

www.stocktitan.net/news/MYGN/myriad-genetic...

Molecular Cancer Detection Breakthrough: Myriad Genetics Patents Game-Changing MRD Testing Methods Myriad Genetics strengthens its position in cancer diagnostics with two new patents for MRD testing technology, advancing automated analysis and patient monitoring capabilities.

#MYGN Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

www.stocktitan.net/news/MYGN/myriad-genetic...

Revolutionary Cancer Testing Integration: Myriad Genetics Slashes Result Times to Under 10 Days Myriad Genetics integrates Prolaris and MyRisk cancer tests with Lumea's BxLink platform, promising faster results delivery and enhanced precision in cancer diagnostics for healthcare providers.

#MYGN Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

www.stocktitan.net/news/MYGN/myriad-genetic...

Revolutionary Prenatal Test Gives Parents Answers 2 Weeks Earlier Than Ever Before Myriad's enhanced Prequel Prenatal Screen achieves breakthrough 12.5% fetal fraction at 8 weeks, winning prestigious SMFM award and enabling earlier diagnostic decisions for expectant parents.

#MYGN Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference

www.stocktitan.net/news/MYGN/myriad-genetic...

Myriad Genetics Doubles Cancer Testing Rates with Revolutionary Online Screening Tool Study shows MyGeneHistory® platform achieved 100% increase in hereditary cancer testing completion, with 87% of clinicians reporting enhanced confidence in risk assessment.

#MYGN Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

www.stocktitan.net/news/MYGN/myriad-genetic...

Myriad Genetics Reports 11% Revenue Growth to $838M in 2024, Despite Wider Net Loss Myriad Genetics delivers preliminary Q4 results with revenues reaching $211M, up 7% YoY. Full-year revenue hits $838M, though GAAP losses persist. Cash position strengthens to $102M.

#MYGN Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance

www.stocktitan.net/news/MYGN/myriad-genetic...